Tesamorelin (off-label)

What it's for

Tesamorelin is a growth-hormone–releasing hormone analog. The FDA-approved brand product is Egrifta for a specific HIV-related abdominal fat condition. This library entry flags compounded versions that are not that brand product.

What it does for the body

Approved Egrifta reduces visceral abdominal fat in HIV lipodystrophy per label. Compounded tesamorelin products are not automatically equivalent in quality, legality, or labeling. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.

What it targets

It turns on GHRH (growth-hormone–releasing hormone, a brain signal that asks the pituitary to release growth hormone) receptors (landing spots on cells) to raise growth hormone pulses. Imagine a growth hormone thermostat nudge — the approved product's evidence package belongs to Egrifta. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.

Research context

Bottom line for readers: Tesamorelin (off-label) is best treated as a research-interest topic. Early papers can be fascinating; they are not a green light for self-experimentation.

Studied for (literature interest)

• Hormones research interest (educational tag)

Cautions (educational)

• Educational only — not medical advice.
• DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.

Citations / starters

• FDA search: Tesamorelin (off-label) — FDA.gov search
• ClinicalTrials.gov search: Tesamorelin (off-label) — U.S. clinical trials registry
• Drugs@FDA search: Tesamorelin (off-label) — FDA drug database (if approved)
• PubMed search: Tesamorelin (off-label) — NCBI PubMed
• PubMed Central search: Tesamorelin (off-label) — NCBI PMC

Reference

No ref on file.